How long has tirzepatide been used, and what does the evidence actually show?

The biggest misconception: tirzepatide is not a medicine that appeared overnight

A common concern is that tirzepatide is too new to trust. That is understandable given how quickly it entered public conversation, but the concern sits awkwardly alongside the actual timeline. Eli Lilly began human studies in the mid-2010s. The large SURPASS clinical programme (focused on type 2 diabetes) enrolled tens of thousands of participants across multiple trials from 2019, producing a dense body of published evidence before the medicine reached any pharmacy shelf. If you want to understand the full arc of that research, the history of tirzepatide's clinical study programme covers it in more detail.

The SURMOUNT programme, specifically examining weight management, launched in 2020. SURMOUNT-1 (the headline trial) ran for 72 weeks and randomised 2,539 adults without diabetes. Results published in the New England Journal of Medicine showed average weight reductions of roughly 20–21% at the 15 mg dose. Those figures are not projections; they are measured outcomes from a controlled trial that concluded before the UK licence was granted. By the time Mounjaro reached a UK pharmacy, clinicians already had two years of SURMOUNT data to work with.

UK approval came in November 2023 for weight management, and NICE formally recommended tirzepatide in December 2024 under technology appraisal TA1026. NICE's process requires robust evidence of both benefit and safety, approval is not automatic. So while tirzepatide is relatively young compared with, say, metformin, calling it untested misreads the timeline by several years.

How the trial data translates to a practical track record

A medicine's real-world track record is built in two ways: controlled trial data and post-approval safety surveillance. Tirzepatide has both. The SURPASS diabetes trials and the SURMOUNT weight-management programme together cover a large and varied population. SURMOUNT-5, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4 mg in a 72-week open-label trial and found greater average weight reduction with tirzepatide, further extending the evidence base. You can read more about how quickly effects are typically seen on the page covering how long tirzepatide takes to work.

Post-approval, the MHRA's Black Triangle (▼) designation means that any suspected side effects are collected and reviewed more actively than for older medicines. This is a standard and expected feature of medicines that are still within their first few post-approval years, not an indication of unresolved safety concerns. The NHS patient information page for tirzepatide on nhs.uk reflects the current agreed safety profile. If you want to report a suspected side effect yourself, you can do so via the MHRA Yellow Card scheme.

One practical footnote worth knowing: tirzepatide is stored in the fridge, typically the door shelf, and most people find building the weekly injection into an existing routine (Sunday evening before the week starts, for example) helps with consistency. A small detail, but one that affects how reliably the medicine works over the months a trial or treatment course runs.

What the treatment timeline looks like for patients today

Understanding how long tirzepatide has been used also means understanding its licensing scope. In the UK, Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension or type 2 diabetes. NICE's recommendation in TA1026 applies to NHS use for adults with a BMI of 35 or above plus at least one weight-related comorbidity, though NHS access is being phased in gradually. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

For those considering treatment now, the question of how long tirzepatide has been used is really a question about confidence in the evidence, and by mid-2026 there is a meaningful answer. Multiple large trials, a formal NICE appraisal, ongoing MHRA surveillance, and a growing body of real-world clinical experience all sit behind it. Questions about how long a course typically lasts are separate but related; the page on how long you can take tirzepatide covers that. For the comparison with Mounjaro's diabetes use timeline, the history of Mounjaro in diabetes treatment provides additional context.

If you are weighing up private treatment, our clinical team reviews every consultation personally, a prescriber, not an automated system, reads your answers. And if cost is part of your thinking, a straightforward overview of what the UK market for Mounjaro looks like is worth a read before you decide.